|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Investment in marketable securities | ||||||||||||||||||||
| Receivables, net (including amounts from related parties) | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total receivables, net (including amounts from related parties) | ||||||||||||||||||||
| Income taxes receivable | ||||||||||||||||||||
| Other receivables | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Loans receivable | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total loans receivable | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Non-current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Income taxes receivable, net of current portion | ||||||||||||||||||||
| Loans receivable, net of current portion | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Total loans receivable, net of current portion | ||||||||||||||||||||
| Investments in other entities – equity method | ||||||||||||||||||||
| Investments in privately held entities | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total non-current assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities, Mezzanine Deficit, and Stockholders' Equity | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Fiduciary accounts payable | ||||||||||||||||||||
| Income taxes payable | ||||||||||||||||||||
| Medical liabilities | ||||||||||||||||||||
| Dividend payable | ||||||||||||||||||||
| Finance lease liabilities | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Current portion of long-term debt | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Non-current liabilities | ||||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||||
| Finance lease liabilities, net of current portion | ||||||||||||||||||||
| Operating lease liabilities, net of current portion | ||||||||||||||||||||
| Long-term debt, net of current portion and deferred financing costs | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total non-current liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation | ||||||||||||||||||||
| Mezzanine deficit | ||||||||||||||||||||
| Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation (“APC”) | ||||||||||||||||||||
| Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation ("APC") | ||||||||||||||||||||
| Stockholders’ equity | ||||||||||||||||||||
| Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, and zero shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Total preferred stock, $0.001 par value per share; 5,000,000 shares authorized, and zero shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Common stock, $0.001 par value per share; 100,000,000 shares authorized, 49,226,943 and 48,885,358 shares issued and outstanding, excluding 10,695,758 and 10,571,011 treasury shares, as of June 30, 2026 and December 31,2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Non-controlling interests | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities, mezzanine deficit, and stockholders' equity | ||||||||||||||||||||
Loading...
